Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCambridge Cog Regulatory News (COG)

Share Price Information for Cambridge Cog (COG)

Share Price is delayed by 15 minutes
Get Live Data
35.00    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 2.00 (5.882%)
Market Cap: £16.29m
COG Live PriceLast checked at - London Stock Exchange

Intraday Cambridge Cog Share Chart

Holding(s) in Company

29 Aug 2019 14:20

RNS Number : 6018K
Cambridge Cognition Holdings PLC
29 August 2019
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

CAMBRIDGE COGNITION HOLDINGS PLC

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

CANACCORD GENUITY GROUP INC

City and country of registered office (if applicable)

VANCOUVER, CANADA

4. Full name of shareholder(s) (if different from 3.)v

Name

DISCRETIONARY CLIENTS

City and country of registered office (if applicable)

As above

5. Date on which the threshold was crossed or reachedvi:

27 AUGUST 2019

6. Date on which issuer notified (DD/MM/YYYY):

29 AUGUST 2019

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

13.7446

13.7446

24,170,093

Position of previous notification (if

applicable)

14.9778

14.9778

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

GB00B8DV9647

3,322,080

13.7446

SUBTOTAL 8. A

3,322,080

13.7446

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

X

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Canaccord Genuity Group Inc.

13.7446

13.7446

Canaccord Genuity Wealth Group Holdings Limited

13.7446

13.7446

Canaccord Genuity Wealth Group Holdings (Jersey) Limited

13.7446

13.7446

Canaccord Genuity Wealth Group Limited

13.7446

13.7446

Canaccord Genuity Wealth Limited

1.0246

1.0246

Hargreave Hale Ltd

12.7200

12.7200

 

 

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional informationxvi

 

Place of completion

BLACKPOOL, ENGLAND

Date of completion

29 AUGUST 2019

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLPLMJTMBBTBPL
Date   Source Headline
20th Apr 20237:00 amRNSNotice of Results
12th Apr 20237:00 amRNS£2.1 million contracts for rare disease trials
21st Mar 20237:00 amRNSBlock Admission Application & Exercise of Options
6th Feb 20237:00 amRNSDirector/PDMR Share Purchases
31st Jan 20237:00 amRNSTrading Update
30th Jan 20231:14 pmRNSHolding(s) in Company
18th Jan 20231:14 pmRNSHolding(s) in Company
18th Jan 202312:22 pmRNSHolding(s) in Company
17th Jan 20235:54 pmRNSHolding(s) in Company
17th Jan 20234:06 pmRNSHolding(s) in Company
13th Jan 20235:09 pmRNSHolding(s) in Company
11th Jan 20237:00 amRNSAcquisition of Winterlight Labs Inc
24th Nov 20227:00 amRNSStrategic Partnership for Chinese Market Expansion
19th Oct 20227:00 amRNS£1.1 million eCOA contract win
12th Oct 20227:00 amRNSAcquisition of eClinicalHealth Limited
20th Sep 20227:00 amRNSInterim Results
1st Sep 20227:00 amRNS£2.2m neurodegenerative disease trial contract
17th Aug 20227:00 amRNSAlzheimer’s Disease Validation for NeuroVocalix
3rd Aug 20222:55 pmRNSDirectorate Change
28th Jul 20227:00 amRNSPTSD trials with top 10 pharma company & US DoD
26th Jul 20227:00 amRNSGrant of Options
22nd Jul 202211:05 amRNSSecond Price Monitoring Extn
22nd Jul 202211:00 amRNSPrice Monitoring Extension
22nd Jul 20227:00 amRNSDirector/PDMR Share Purchases
21st Jul 20227:00 amRNSTrading Update and Notice of Results
14th Jul 202211:06 amRNSSecond Price Monitoring Extn
14th Jul 202211:00 amRNSPrice Monitoring Extension
30th Jun 20225:43 pmRNSHolding(s) in Company
8th Jun 20223:14 pmRNSResult of AGM
16th May 20224:35 pmRNSPosting of Annual Report & Notice of AGM
12th Apr 20227:00 amRNSResults for the year ended 31 December 2021
6th Apr 20227:00 amRNSSenior Management Appointments
31st Mar 20227:00 amRNSNotice of Results
29th Mar 20222:06 pmRNSSecond Price Monitoring Extn
29th Mar 20222:00 pmRNSPrice Monitoring Extension
28th Mar 20224:41 pmRNSSecond Price Monitoring Extn
28th Mar 20224:35 pmRNSPrice Monitoring Extension
28th Mar 20227:00 amRNS£1 million contract for pivotal autoimmune trial
24th Mar 20227:00 amRNSAppointment of Nominated Adviser and Joint Broker
4th Feb 202212:06 pmRNSHolding(s) in Company
2nd Feb 20227:00 amRNS£2.1 million contract
27th Jan 20227:00 amRNSTrading Update
10th Jan 20227:00 amRNSNew Major Pharma Client for Schizophrenia Trials
16th Dec 20217:00 amRNSElectronic Clinical Outcomes Assessment Contract
9th Dec 20217:00 amRNS£1.0m Schizophrenia clinical trial contract
22nd Nov 202111:50 amRNSHolding(s) in Company
16th Nov 20217:00 amRNSGrant of Options
2nd Nov 20217:00 amRNSDirectorate Change
26th Oct 20217:00 amRNSContract for pivotal schizophrenia clinical trial
6th Oct 202110:06 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.